Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer

"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."